If approved, Regeneron and Tessera's TSRA-196 could become the first curative therapy to reach patients with AATD, who have ...

The "Rising Stars in Drug Metabolism and Transport 2025/2026" highlights the groundbreaking work of early-career researchers ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

In the 1980s, the human immunodeficiency virus (HIV) was a global scourge, decimating communities. When it was identified in the blood products supply chain, people were terrified.

According to MarketsandMarkets™, the Preclinical Imaging Market is projected to grow from about USD 3.53 billion in 2025 to ...

The convergence of genomics, systems biology, and artificial intelligence is transforming the landscape of drug discovery. Modern genomic technologies now ...

IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the clearance of an investigational new drug (IND) ...

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the "Company” or "Exo Bio”), operating as a leading U.S. biotechnology ...

Scientists aim to lift the flight ban on lab animals, citing challenges in drug discovery and research transportation.

A novel, automated method for manufacturing lung organoids could aid in the discovery of new lung disease therapies.